Altoida

Altoida Partners With GN Group to Research and Develop New Cognitive Assessment Technology to Detect Mild Cognitive Impairment

February 7, 2022Neelem Sheikh

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us